{"id":"NCT01729871","sponsor":"Janssen Scientific Affairs, LLC","briefTitle":"A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","officialTitle":"A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2012-11-20","resultsPosted":"2015-11-10","lastUpdate":"2017-03-06"},"enrollment":253,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atrial Fibrillation"],"interventions":[{"type":"DRUG","name":"rivaroxaban","otherNames":[]},{"type":"DRUG","name":"uninterrupted vitamin K antagonist (VKA)","otherNames":[]}],"arms":[{"label":"rivaroxaban","type":"EXPERIMENTAL"},{"label":"vitamin K antagonist (VKA)","type":"EXPERIMENTAL"}],"summary":"The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as measured by post-procedure major bleeding events.","primaryOutcome":{"measure":"Number of Participants With Incidence of Post-Procedure Major Bleeding Events","timeFrame":"Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure","effectByArm":[{"arm":"Rivaroxaban","deltaMin":0,"sd":null},{"arm":"Vitamin K Antagonist","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":44,"countries":["United States","Belgium","France","Germany","United Kingdom"]},"refs":{"pmids":["25975659"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":123},"commonTop":["Atrial fibrillation","Haematoma","Fatigue"]}}